NONDISCRIMINATION AND CONFIDENTIALITY STATEMENT 

As a participant of the BHOC: Orthopedic Joint Replacement Series involved in the evaluation and improvement of quality of care and service, I recognize that confidentiality is vital. Therefore, I agree to respect and maintain the confidentiality of all discussions, records and information generated in connection within the BHOC: Orthopedic Joint Replacement Series and to make no voluntary disclosure of such information except to persons authorized. As a participant of the BHOC: Orthopedic Joint Replacement Series, I will ensure that my participation in the peer review process and discussions will be made in a non-discriminatory manner and will not be made based on the patients' race, ethnic/national identity, gender, age, sexual orientation, or patient population for which they serve.

DISCLOSURE STATEMENT 

Juan Carlos Suarez, M.D., director for this educational activity, is a consultant for Depuy and Medacta USA and has received royalties from Corin USA, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

Charles Lawrie, M.D., moderator for this educational activity, is a consultant for Zimmer Biomet, Smith and Nephew, Mizuho OSI, Medtronic, Ganymed Robotics, Ignite Orthomotion, Fios Health and has received royalties from Zimmer Biomet and is a shareholder of Fios Health, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

Aldo Riesgo, M.D., faculty for this educational activity, is a consultant for Zimmer Biomet, Stryker, Sanara MedTech and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

Richard D. Murray, MD, Fermin Prieto, MD, Denise E. Smith, MD, fellows of this educational activity have no relevant financial relationships with ineligible companies* to disclose.

•    GME coordinators and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.
*Ineligible companies – Companies whose primary business is producing, marketing, selling, reselling or distributing healthcare products used by or on patients.